Transgenic Rescue of Adipocyte Glucose-dependent Insulinotropic Polypeptide Receptor Expression Restores High Fat Diet-induced Body Weight Gain
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
The glucose-dependent insulinotropic polypeptide receptor (GIPr) has been implicated in high fat diet-induced obesity and is proposed as an anti-obesity target despite an uncertainty regarding the mechanism of action. To independently investigate the contribution of the insulinotropic effects and the direct effects on adipose tissue, we generated transgenic mice with targeted expression of the human GIPr to white adipose tissue or beta-cells, respectively. These mice were then cross-bred with the GIPr knock-out strain. The central findings of the study are that mice with GIPr expression targeted to adipose tissue have a similar high fat diet -induced body weight gain as control mice, significantly greater than the weight gain in mice with a general ablation of the receptor. Surprisingly, this difference was due to an increase in total lean body mass rather than a gain in total fat mass that was similar between the groups. In contrast, glucose-dependent insulinotropic polypeptide-mediated insulin secretion does not seem to be important for regulation of body weight after high fat feeding. The study supports a role of the adipocyte GIPr in nutrient-dependent regulation of body weight and lean mass, but it does not support a direct and independent role for the adipocyte or beta-cell GIPr in promoting adipogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297
Self-citationInhibition of gastric inhibitory polypeptide signaling prevents obesity
Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., et al. (2002) · Nature Medicine · doi:10.1038/nm727 · Cited by 963
Self-citationCarey, A. L., Steinberg, G. R., Macaulay, S. L., Thomas, W. G., Holmes, A. G., Ramm, G., Prelovsek, O., Hohnen-Behrens, C., Watt, M. J., James, D. E., et al. (2006) · Diabetes · doi:10.2337/db05-1404 · Cited by 898
Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats
Tang-Christensen, M., Larsen, P. J., Goke, R., Fink-Jensen, A., Jessop, D. S., Moller, M., & Sheikh, S. P. (1996) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1996.271.4.r848 · Cited by 597
Miyawaki, K., Yamada, Y., Yano, H., Niwa, H., Ban, N., Ihara, Y., Kubota, A., Fujimoto, S., Kajikawa, M., Kuroe, A., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.14843 · Cited by 454
Self-citationMeeran, K., O’Shea, D., Edwards, C. M. B., Turton, M. D., Heath, M. M., Gunn, I., Abusnana, S., Rossi, M., Small, C. J., Goldstone, A. P., et al. (1999) · Endocrinology · doi:10.1210/endo.140.1.6421 · Cited by 303
Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure
Hansotia, T., Maida, A., Flock, G., Yamada, Y., Tsukiyama, K., Seino, Y., & Drucker, D. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci25483 · Cited by 290
Self-citationFunctional GIP Receptors Are Present on Adipocytes
Yip, R. G.-C., Boylan, M. O., Kieffer, T. J., & Wolfe, M. M. (1998) · Endocrinology · doi:10.1210/endo.139.9.6288 · Cited by 237
Gastric Inhibitory Polypeptide Enhanced Lipoprotein Lipase Activity in Cultured Preadipocytes
Eckel, R. H., Fujimoto, W. Y., & Brunzell, J. D. (1979) · Diabetes · doi:10.2337/diab.28.12.1141 · Cited by 219
Cited by
Pharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500
How May GIP Enhance the Therapeutic Efficacy of GLP-1?
Samms, R. J., Coghlan, M. P., & Sloop, K. W. (2020) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2020.02.006 · Cited by 419
Nauck, M. A., Quast, D. R., Wefers, J., & Pfeiffer, A. F. H. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14496 · Cited by 388
Adriaenssens, A. E., Biggs, E. K., Darwish, T., Tadross, J., Sukthankar, T., Girish, M., Polex-Wolf, J., Lam, B. Y., Zvetkova, I., Pan, W., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.07.013 · Cited by 324
Killion, E. A., Wang, J., Yie, J., Shi, S. D.-H., Bates, D., Min, X., Komorowski, R., Hager, T., Deng, L., Atangan, L., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aat3392 · Cited by 237
“Transgenic rescue of adipocyte GIPR in GIPR KO mice restored HFD-induced body weight gain (33), and mice with adipocyte-specific GIPR KO are protected against DIO (32), suggesting a role for adipocyte GIPR in body weight regulation.”
BackgroundReappraisal of GIP Pharmacology for Metabolic Diseases
Finan, B., Müller, T. D., Clemmensen, C., Perez-Tilve, D., DiMarchi, R. D., & Tschöp, M. H. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.03.005 · Cited by 180
Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes
Capozzi, M. E., DiMarchi, R. D., Tschöp, M. H., Finan, B., & Campbell, J. E. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00117 · Cited by 153
Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms
Campbell, J. E. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101139 · Cited by 133
“To directly test this, BAT-specific Gipr knockout mice (GiprMyf5 ) were generated using Myf5-Cre mice [47], which produced Cre recombinase activity in classical brown adipocytes and skeletal muscle; the latter tissue was muted in this experiment since muscle does not express GIPR [47,51,58].”
BackgroundMethodInfluentialKillion, E. A., Lu, S.-C., Fort, M., Yamada, Y., Véniant, M. M., & Lloyd, D. J. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz002 · Cited by 94
Pharmacological antagonism of the incretin system protects against diet-induced obesity
Svendsen, B., Capozzi, M. E., Nui, J., Hannou, S. A., Finan, B., Naylor, J., Ravn, P., D'Alessio, D. A., & Campbell, J. E. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2019.11.018 · Cited by 67
Searching for the physiological role of glucose‐dependent insulinotropic polypeptide
Holst, J. J., Windeløv, J. A., Boer, G. A., Pedersen, J., Svendsen, B., Christensen, M., Torekov, S., Asmar, M., Hartmann, B., & Nissen, A. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12488 · Cited by 36
Self-citationIrwin, N., Gault, V. A., O’Harte, F. P. M., & Flatt, P. R. (2020) · Peptides · doi:10.1016/j.peptides.2019.170203 · Cited by 27
Incretin receptor agonism rapidly inhibits AgRP neurons to suppress food intake in mice
McMorrow, H. E., Cohen, A. B., Lorch, C. M., Hayes, N. W., Fleps, S. W., Frydman, J. A., Xia, J. L., Samms, R. J., & Beutler, L. R. (2025) · Journal of Clinical Investigation · doi:10.1172/jci186652 · Cited by 12
“By contrast, other studies have shown that global GIPR-KO mice are protected from both obesity and insulin resistance when fed a high-fat diet (31–35), and GIPR antagonism coupled with GLP-1R agonism leads to weight loss in early clinical trials and mouse models (36, 37), possibly by preventing…”
Metadata
- Authors
- Ugleholdt, R., Pedersen, J., Bassi, M. R., Füchtbauer, E.-M., Jørgensen, S. M., Kissow, H.-L., Nytofte, N., Poulsen, S. S., Rosenkilde, M. M., Seino, Y., Thams, P., Holst, P. J., & Holst, J. J.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2011-12
- Volume
- 286
- Issue
- 52
- Pages
- 44632-44645
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2059985282
- Cited by
- 49
- References
- 25
- FWCI
- 1.24
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.